By Kelly Cloonan
Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech.
The stock rose 7% to $2.99 on Friday. Shares have lost 1% over the past 12 months.
The biopharmaceutical company said Thursday that the European Patent Office has confirmed the validity of its amended patent for split poly-A tail technology, which improves expression of the protein encoded on an mRNA construct to enhance the efficacy of certain vaccines.
BioNTech first filed a lawsuit regarding the patent in 2023.
After Thursday's ruling, the Regional Court Düsseldorf will decide if the amended patent has been infringed in a hearing scheduled for July 1.
"Today's decision marks an important step on our path that we expect will lead to recognition of CureVac's major contribution to safe and efficacious Covid-19 vaccines as the earliest pioneer in mRNA technology," said CureVac Chief Executive Dr. Alexander Zehnder.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
March 28, 2025 12:45 ET (16:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.